Back to Journals » Substance Abuse and Rehabilitation » Volume 7

Primary care for opioid use disorder

Authors Mannelli P, Wu L

Received 9 June 2016

Accepted for publication 10 June 2016

Published 16 August 2016 Volume 2016:7 Pages 107—109

DOI https://doi.org/10.2147/SAR.S69715

Checked for plagiarism Yes


Paolo Mannelli,1 Li-Tzy Wu1–4

1Department of Psychiatry and Behavioral Sciences, 2Department of Medicine, 3Duke Clinical Research Institute, Duke University Medical Center, 4Center for Child and Family Policy, Sanford School of Public Policy, Duke University, Durham, NC, USA

Recent reports on prescription opioid misuse and abuse have described unprecedented peaks of a national crisis and the only answer is to expand prevention and treatment, including different levels of care.1 Nonetheless, concerns remain about the ability of busy primary care settings to manage problem opioid users along with other patients. In particular, proposed extensions of buprenorphine treatment, a critically effective intervention for opioid use disorder (OUD), are cautiously considered due to the potential risk of misuse or abuse.2 General practitioners are already facing this burden daily in the treatment of chronic pain, and expert supervision and treatment model adjustment are needed to help improve outcomes. Approximately 20% of patients in primary care have noncancer pain symptoms, with most of them receiving opioid prescriptions by their physicians, and their number is increasing.3 Pain diagnoses are comparable in severity to those of tertiary centers and are complicated by significant psychiatric comorbidity, with a measurable lifetime risk of developing OUD.4,5 Some primary care physicians report frustration about opioid abuse and diversion by their patients; support from pain specialists would improve their competence, the quality f their performance, and the ability to identify patients at risk of opioid misuse.6 Thus, buprenorphine treatment should not be adding to a complex clinical scenario. To this end, the promising models of care emphasize the integration of medical with psychological and pharmacological expertise for the management of OUD.

 

Acknowledgments

Paolo Mannelli and Li-Tzy Wu have received research support from the US National Institutes of Health (UG1DA040317, R01MD007658, and R01DA019623). The sponsoring agency had no further role in the writing of the report or the decision to submit the paper for publication. The opinions expressed in this paper are solely those of the authors.

Disclosure

Paolo Mannelli has received research funding from Orexo and Alkermes Inc and has served on a Scientific Advisory Board for Alkermes Inc. The authors have no other conflicts of interest to disclose.

References

1.

Kanouse AB, Compton P. The epidemic of prescription opioid abuse, the subsequent rising prevalence of heroin use, and the federal response. J Pain Palliat Care Pharmacother. 2015;29(2):102–114.

2.

Li X, Shorter D, Kosten TR. Buprenorphine prescribing: to expand or not to expand. J Psychiatr Pract. 2016;22(3):183–192.

3.

Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain — United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49.

4.

Fink-Miller EL, Long DM, Gross RT. Comparing chronic pain treatment seekers in primary care versus tertiary care settings. J Am Board Fam Med. 2014;27(5):594–601.

5.

Weiss RD, Potter JS, Griffin ML, et al. Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain. J Subst Abuse Treat. 2014;47(2):140–145.

6.

Jamison RN, Scanlan E, Matthews ML, Jurcik DC, Ross EL. Attitudes of primary care practitioners in managing chronic pain patients prescribed opioids for pain: a prospective longitudinal controlled trial. Pain Med. 2016;17(1):99–113.

7.

Komaromy M, Duhigg D, Metcalf A, et al. Project ECHO (Extension for Community Healthcare Outcomes): a new model for educating primary care providers about treatment of substance use disorders. Subst Abus. 2016;37(1):20–24.

8.

Hutchinson E, Catlin M, Andrilla CH, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128–133.

9.

Rosenblatt RA, Andrilla CH, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. The Annals of Family Medicine. 2015;13(1):23–26.

10.

Haddad MS, Zelenev A, Altice FL. Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers. J Urban Health. 2015;92(1):193–213.

11.

Providers’ Clinical Support System for Medication Assisted Treatment [PCSSMAT]. Available from: http://pcssmat.org/. Accessed May 30, 2016.

12.

Marsch LA, Guarino H, Acosta M, et al. Web-based behavioral treatment for substance use disorders as a partial replacement of standard methadone maintenance treatment. J Subst Abuse Treat. 2014;46(1):43–51.

13.

LaBelle CT, Han SC, Bergeron A, Samet JH. Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts Collaborative Care Model in Community Health Centers. J Subst Abuse Treat. 2016;60:6–13.

14.

Weiss L, Egan JE, Botsko M, Netherland J, Fiellin DA, Finkelstein R. The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment. J Acquir Immune Defic Syndr. 2011;56 (Suppl 1):S7–S13.

15.

Tanner C, Gans D, White J, Nath R, Pohl J. Electronic health records and patient safety: co-occurrence of early EHR implementation with patient safety practices in primary care settings. Appl Clin Inform. 2015;6(1):136–147.

16.

Brady JE, Wunsch H, DiMaggio C, Lang BH, Giglio J, Li G. Prescription drug monitoring and dispensing of prescription opioids. Public Health Rep. 2014;129(2):139–147.

17.

U.S. Food and Drug Administration (FDA), 2016. FDA approves first buprenorphine implant for treatment of opioid dependence. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503719.htm. Accessed on July 17, 2016.

18.

Mannelli P, Peindl KS, Wu LT. Pharmacological enhancement of naltrexone treatment for opioid dependence: a review. Subst Abuse Rehabil. 2011;2011(2):113–123.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]